Related Experiment Videos
[Intravitreal chemotherapy for intraocular lymphoma]
H Helbig1, Th Cerny, M D de Smet
1Klinik für Augenkrankheiten, Kantonsspital St.Gallen, Switerland. horst.helbig@kssg.ch
Summary
Intravitreal chemotherapy effectively treats recurring ocular lymphoma after initial treatments. This method achieved tumor regression and maintained disease-free status for up to two years in patients.
Area of Science:
- Oncology
- Ophthalmology
Background:
- Primary central nervous system (CNS) and intraocular non-Hodgkin's lymphoma often recurs after initial systemic chemotherapy and radiotherapy.
- Radiotherapy, a common secondary treatment, has limitations due to actinic complications, allowing only a single application.
Observation:
- New tumor growth is frequently observed even after a good primary therapeutic response.
- Intraocular recurrence presents a challenge for treatment due to the limitations of radiotherapy.
Findings:
- Intravitreal chemotherapy, using methotrexate and dexamethasone, demonstrated efficacy in treating ocular recurrences.
- This treatment led to regression of intraocular tumors and vision improvement within weeks of initiation.
Implications:
- Intravitreal chemotherapy offers a viable and effective treatment option for ocular recurrences of primary CNS and intraocular lymphoma.
- The treatment achieved recurrence-free status for up to two years, suggesting long-term efficacy.